Agriculture & Natural Solutions Acquisition Corp Ordinary Shares - Class A ANSC 深 沪
等待开盘 10-24 09:30:00 美东时间
11.11
-0.010
-0.09%
华盛通- 最 高11.12
- 今 开11.12
- 成交量 1.50万股
- 最 低 11.11
- 昨 收 11.12
- 总市值 4.79亿
- 52周最高 11.12
- 市盈率 静 366.67
- 换手率 0.03%
- 52周最低 10.38
- 委 比 -26.33%
- 总股本 4312.50万
- 历史最高 11.12
- 量 比 0.05
- 振 幅 0.09%
- 历史最低 10.05
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多KBR, Inc. (KBR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Oct. 22, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against KBR, In...
10-23 03:28
Agriculture & Natural Solutions Files Proxy Statement
The latest announcement is out from Agriculture & Natural Solutions Acquisi...
10-15 04:55
ATTENTION NYSE: KBR INVESTORS: Contact Berger Montague About a KBR, Inc. Class Action Lawsuit
PHILADELPHIA, Oct. 6, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against KBR, Inc. (NYSE: KBR) ("KBR" or the "Company") on behalf ...
10-07 03:15
KBR, Inc. (KBR) Faces Securities Class Action Amid TRANSCOM Contract Termination-Hagens Berman
SAN FRANCISCO, Sept. 22, 2025 /PRNewswire/ -- A new class-action lawsuit is targeting KBR, Inc. (NYSE: KBR), alleging the company made misleading statements to investors in the weeks leading...
09-23 00:45
CERo Therapeutics Secures U.S. And Japanese Patents For CER-1236
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technologySOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE
09-09 20:18
【太平洋医药】医药生物行业周报：资金现跷跷板效应，持续关注创新药催化（附PD-(L)1/VEGF专题研究）
（来源：市场投研资讯） 摘要 本周观点 本周，我们梳理了PD-(L)1/VEGF作用机制、在研产品以及催化剂。 关注PD-(L)1/VEGF赛道，202...
09-01 14:59
Rhythm Pharmaceuticals Announces The FDA Has Accepted Its Supplemental New Drug Application For Setmelanotide To Treat Acquired Hypothalamic Obesity
U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 --– European Medicines Agency accepts and validates submission for Type II variation MAA for
08-21 04:03
Surmodics Raises FY2025 Adj EPS Guidance from $(0.62)-$(0.42) to $(0.35)-$(0.20) vs $(0.55) Est; Raises FY2025 Sales Guidance from $114.000M-$117.000M to $116.500M-$118.500M vs $115.686M Est
Fiscal Year 2025 Financial GuidanceSurmodics is increasing its fiscal 2025 total revenue to a range of $116.5 million to $118.5 million, representing a decrease of 8% to 6% compared to fiscal 2024. Excluding SurVeil DCB
08-08 19:05
CERo Therapeutics Doses Second Patient In Phase 1 AML Trial; Reports Early Pharmacokinetic Data With More Than Seven Days Passed Following The Second Patient's Infusion, Monitoring Continues For Key Safety, Tolerability, And Efficacy Endpoints
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic resultsSOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE
07-31 20:11
Reported Saturday, Rhythm Pharmaceuticals Reports Statistically Significant BMI Reductions In Children And Adults Across Multiple Doses And Subgroups In TRANSCEND And SIGNAL Trials
Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –- Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with
07-14 14:51
